TY - JOUR

T1 - Metformin er en mulig glukagonlignende peptid-1-stimulator

AU - Bahne, Emilie

AU - Brønden, Andreas

AU - Vilsbøll, Tina

AU - Knop, Filip Krag

PY - 2018

Y1 - 2018

N2 - Metformin is an oral anti-hyperglycaemic drug used as first-line treatment of Type 2 diabetes. It is more effective when administered orally than when administered intravenously, and metformin formulations, which prolong the time residing in the gut are the most potent. This indicates that the intestine plays an essential role in metformin's mode of action. Metformin also increases plasma concentrations of the glucose-lowering gut incretin hormone glucagon-like peptide-1 (GLP-1). This metformin-induced GLP-1 increment may constitute an important link between the gut and the glucose-lowering effect of metformin.

AB - Metformin is an oral anti-hyperglycaemic drug used as first-line treatment of Type 2 diabetes. It is more effective when administered orally than when administered intravenously, and metformin formulations, which prolong the time residing in the gut are the most potent. This indicates that the intestine plays an essential role in metformin's mode of action. Metformin also increases plasma concentrations of the glucose-lowering gut incretin hormone glucagon-like peptide-1 (GLP-1). This metformin-induced GLP-1 increment may constitute an important link between the gut and the glucose-lowering effect of metformin.

KW - Bile Acids and Salts/metabolism

KW - Dipeptidyl-Peptidase IV Inhibitors/metabolism

KW - Gastrointestinal Microbiome/drug effects

KW - Glucagon-Like Peptide 1/metabolism

KW - Humans

KW - Metformin/metabolism

M3 - Tidsskriftartikel

C2 - 29559078

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 12

M1 - V07170516

ER -